Form 4: 4D Molecular Therapeutics Executive Granted Stock Options

Robert Young Kim, Chief Medical Officer of 4D Molecular Therapeutics, was granted stock options for 92,300 shares at an exercise price of $4.14 on March 6, 2025.

Summary

• Robert Young Kim, the Chief Medical Officer of 4D Molecular Therapeutics, was granted stock options.
• The transaction occurred on March 6, 2025.
• Kim received options for 92,300 shares of common stock.
• The exercise price for the options is $4.14 per share.
• The options vest monthly, starting March 6, 2025, over four years.
• The options expire on March 5, 2035.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral positive.

Positives

• The granting of stock options to the Chief Medical Officer aligns his interests with the company's long-term success.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The stock options will vest over a four-year period, incentivizing the executive to remain with the company and contribute to its growth.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in the biotechnology industry.
• The size of the grant and the vesting schedule are typical for executives at similar stage companies.
• Comparing the grant to those of executives at companies like CRISPR Therapeutics or Editas Medicine would provide a more detailed benchmark.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
• The grant incentivizes the executive, potentially benefiting employees through improved company performance.

Key Dates